The Board of Directors of Balaxi Pharmaceuticals Limited, in their meeting held on January 28, 2026, approved the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025. For the quarter ended December 31, 2025 (Q3 FY26), the company reported a consolidated total income of ₹82.45 Crores, representing a significant increase of 42.75% compared to the previous quarter’s ₹57.76 Crores and a 6.76% growth from ₹77.23 Crores in the corresponding quarter of the previous year. The consolidated net profit for Q3 FY26 stood at ₹6.12 Crores, marking a substantial recovery of 2,814% from the preceding quarter’s ₹0.21 Crores and a 14.18% increase from ₹5.36 Crores reported in Q3 FY25.

Balaxi Pharmaceuticals Limited is a branded IPR-based pharmaceutical company that specializes in frontier markets across Africa, Central America, and the Caribbean. The company operates a “stock-and-sell” model, supported by an extensive on-ground distribution network including 38 warehouses and a proprietary fleet of vehicles. Balaxi focuses on a diverse portfolio of over 897 registered products, ranging from antibiotics and analgesics to consumer products like oral care. In a major strategic update for 2025, the company successfully completed the construction and infrastructure setup of its first pharmaceutical formulation plant in Jadcherla, Hyderabad, and has obtained a Test Manufacturing Licence. This shift from an asset-light to an “asset-right” model aims to bolster long-term margins and ensure supply chain reliability as the company targets expansion into 20 frontier markets over the next few years. Notable individual investors in the company as of late 2025 include Kunal Mahendra Bhakta (1.86%) and Amol Anand Mantri (1.41%).